## LYME DISEASE CASE REPORT FORM

Form Approved OMB No. 0920-0009 Expiration Date 12-92

Patient's last name	First name	Tele.No	o. ( )
Address	Cit	у	
	Detach before sending to CDC		
State	County	Zip	
Age (yrs.) Sex M F Unspec.	Race — Amer. Indian/Eskimo — Asian/Pacific Isl. — Black — White — Unknown		Hispanic Non Hisp. Unknown
SYMPTOMS AND SIGNS (	OF CURRENT EPISODE (PLEASE	MARK EACH QUEST	ION):
DERMATOLOGIC: Erythema migrans (physician diagn	osed EM at least 5 cm in diamete	er)?[Y]	[N] [?]
RHEUMATOLOGIC:  Arthritis characterized by brief attack NEUROLOGIC:	profile and the second		[N] [?]
Bell's palsy or other cranial neuritis? Radiculoneuropathy? Lymphocytic meningitis? Encephalitis/Encephalomyelitis?		M	[N] [?] [N] [?] [N] [?]
CSF tested for antibodies to B. burgo Antibody to B. burgdorferi higher in C	dorferi? CSF than serum? <sub>"</sub>	M	[N] [?] [N] [?] [N] [?]
2nd or 3rd degree atrioventricular bio		M	[N] [?]
Other clinical:			
Date of onset of first symptoms: //mo dy yr  Was the patient hospitalized for the current ep  Name of antibiotic(s) used this episode?	OTHER HISTORY	[Y]   Use in days	
Was the patient pregnant at the time of illness	3?	M	[N]
Where was the patient most likely exposed?	County	State	
	LABORATÔRY RESULTS Positive Negative I	Equivocal No	ot done/Unknown
Serologic test results: Culture results: Other (specify)			
Physician's name	Person comple (if not the same		
Address	Address		
Telephone Number ()	Telephone Nu	Imper ( )	
	FOR INTERNAL USE ONLY	Date	
State ID No.  LYME DISEASE CASE REPORT FORM CDC 52:50 REV, 1-91	CDC 1D No. 00000	Repo to CS	

This report is authorized by law (Public Health Spiritos Act, 42 USC 241). While your response is voluntary, your cooperation is necessary for the understanding and control of this public health sproblem. Public reporting burden for this collection of information is estimated to average, 10 minutes per response. Send comments regarding this burden estimate or stry other aspect of this collection of information, including suggestions for reducing this burden to PHS Reports Clearance Officer; ATTN: PRA; Hubert H. Humphrey Bg, Rm 721-B; 200 Independence Ave., SW; Washington, DC 20201, and to the Office of Management and Budget; Paperwork Reduction Project (0520-0009); Washington, DC 20503.

CDC 52.60 REV. 1:91

# LYME DISEASE NATIONAL SURVEILLANCE CASE DEFINITION

Lyme disease is a systemic, tick-borne disease with protean manifestations, including dermatologic, rheumatologic, neurologic, and cardiac abnormalities. The best clinical marker for the disease is the initial skin lesion. erythema migrans (EM), that occurs in 60% to 80% of patients.

## A case of Lyme disease is defined as follows:

1. A person with erythema migrans; or

2. A person with at least one late manifestation and laboratory confirmation of infection.

NOTE: It should be emphasized that is an epidemiologic case definition intended for surveillance purposes only.

#### General clinical epidemiologic definitions:

1. Erythema migrans (EM):

For purposes of surveillance, EM is a skin lesion that typically begins as a red macule or papule and expands over a period of days or weeks to form a large round lesion, often with partial central clearing. A solitary lesion must reach at least 5 cm in size. Secondary lesions may also occur. Annular erythematous lesions occuring within several hours of a tick bite represent hypersensitivity reactions and do not qualify as EM. In most patients, the expanding EM lesion is accompanied by other acute symptoms, particularly fatigue, fever, headache, mild stiff neck, arthralgias, or myalgias. These symptoms are typically intermittent. The diagnosis of EM must be made by a physician. Laboratory confirmation is recommended for persons with no known exposure.

#### 2. Late manifestations:

These include any of the following when an alternate explanation is not found.

a. Musculoskeletal system:

Recurrent, brief attacks (weeks or months) of objective joint swelling in one or a few joints sometimes followed by chronic arthritis in one or a few joints. Manifestations not considered as criteria for diagnosis include chronic progressive arthritis not preceded by brief attacks and chronic symmetrical polyarthritis. Additionally, arthralgias, myalgias, or fibromyalgia syndromes alone are not accepted as criteria for musculoskeletal involvement.

b. Nervous system:

Lymphocytic meningitis, cranial neuritis, particularly facial palsy (may be bilateral), radiculoneuropathy or rarely, encephalomyelitis alone or combination. Encephalomyelitis must be confirmed by showing antibody production against B. burgdorferi in the cerebrospinal fluid (CSF), demonstrated by a higher titer of antibody in CSF than in serum. Headache, fatigue, paresthesias, or mild stiff neck alone are not accepted as criteria for neurologic involvement.

c. Cardiovascular system:

Acute onset, high grade (2nd or 3rd degree) atrioventricular conduction defects that resolve in days to weeks and are sometimes associated with myocarditis. Palpitations, bradycardia, bundle branch block, or myocarditis alone are not accepted as criteria for cardiovascular involvement.

3. Exposure:

Exposure is defined as having been in wooded, brushy, or grassy areas (potential tick habitats) in an endemication of the country no more than 30 days prior to the onset of EM. A history of tick bite is not required.

4. Endemic county:

An endemic county is one in which at least 2 definite cases have been previously acquired or a county in which a tick vector has been shown to be infected with B. burgdorferi.

5. Laboratory confirmation:

Laboratory confirmation of infection with B. burgdorferi is established when a laboratory isolates the spirochete from tissue or body fluid, detects diagnostic levels of IgM or IgG antibodies to the spirochete in serum or CSF, or detects a significant change in antibody levels in paired acute and convalescent serum samples. States may determine the criteria for laboratory confirmation and diagnostic levels of antibody. Syphilis and other known causes of biologic false positive serologic test results should be excluded, as appropriate, when laboratory confirmation has been based on serologic testing alone.